SDC1 and acute leukemia: In summary, emerging CAR-T cell therapeutic approaches may become the forefront of the exploitation of proteoglycan antigens, as firmly suggested by the promising preclinical efforts with CAR-T-based approaches targeting CSPG4 and Syndecan-1/CD138 in childhood and adult acute leukemia.